# Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

> **NCT06236997** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Adebrelimab
- **RADIATION:** Radiation Therapy
- **DRUG:** etoposide, carboplatin(EC)

## Key facts

- **NCT ID:** NCT06236997
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-10
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06236997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06236997, "Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06236997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*